NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 38,172 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $33.75, for a total transaction of $1,288,305.00. Following the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $821,913.75. This trade represents a 61.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $32.78, for a total value of $1,127,632.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total value of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Stock Up 0.8%

Shares of NewAmsterdam Pharma stock opened at $32.63 on Wednesday. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00. The firm’s 50 day moving average is $35.46 and its two-hundred day moving average is $31.24. The firm has a market capitalization of $3.70 billion, a P/E ratio of -15.92 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $4.54 million. As a group, research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NAMS has been the subject of a number of research analyst reports. Needham & Company LLC raised their price target on NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Stifel Nicolaus raised their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Leerink Partners reiterated an “outperform” rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. HC Wainwright started coverage on shares of NewAmsterdam Pharma in a research note on Monday, October 20th. They set a “buy” rating and a $52.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, NewAmsterdam Pharma has an average rating of “Moderate Buy” and an average target price of $47.00.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of NAMS. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in NewAmsterdam Pharma by 167.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,804 shares of the company’s stock worth $695,000 after purchasing an additional 12,400 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of NewAmsterdam Pharma by 26.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,510 shares of the company’s stock worth $193,000 after buying an additional 1,156 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after buying an additional 708 shares in the last quarter. Aberdeen Group plc grew its stake in NewAmsterdam Pharma by 10.2% in the 4th quarter. Aberdeen Group plc now owns 729,484 shares of the company’s stock valued at $25,590,000 after acquiring an additional 67,538 shares during the last quarter. Finally, Jaffetilchin Investment Partners LLC purchased a new position in NewAmsterdam Pharma during the 4th quarter valued at about $323,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.